Sialylated glycoproteins
AssigneeMomenta Pharmaceuticals, Inc.
InventorsNathaniel J. WASHBURN, Daniel ORTIZ, John SCHAECK
Life of this patent
Estimating the term…
Abstract
Methods for measuring disialylated Fc glycan in a biological sample are described.
Claims27
An in vitro or ex vivo method for assessing a patient sample to determine the level of IgG1 that is disialylated on the Fc domain in the patient sample, the method comprising:
- providing a patient sample;
- adding a composition comprising detectably labeled EEQYNSTYR-A2F peptide to the sample;
- denaturing and trypsin digesting proteins in the sample to prepare a treated sample;
- subjecting treated sample to LC-MS/MS;
- and
- calculating the level of EEQYNSTYR-A2F peptide in the patient sample.
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
An in vitro or ex vivo method for assessing a patient sample to determine the level of IgG2/3 that is disialylated on the Fc domain in the patient sample, the method comprising:
- providing a patient sample;
- adding a composition comprising detectably labeled EEQFNSTFR-A2F peptide to the sample;
- denaturing and trypsin digesting proteins in the sample to prepare a treated sample;
- subjecting treated sample to LC-MS/MS;
- and
- calculating the level of EEQFNSTFR-A2F peptide in the patient sample.
(canceled)
(canceled)
An in vitro or ex vivo method for assessing a patient sample to determine the level of IgG3/4 that is disialylated on the Fc domain in the patient sample, the method comprising:
- providing a patient sample;
- adding a composition comprising detectably labeled EEQYNSTFR-A2F and/or EEQFNSTYR-A2F peptide to the sample;
- denaturing and trypsin digesting proteins in the sample to prepare a treated sample;
- subjecting treated sample to LC-MS/MS;
- and
- calculating the level of EEQYNSTFR-A2F and/or EEQFNSTYR-A2F peptide in the patient sample.
A composition comprising:
- detectably labeled EEQYNSTFR-A2F and/or EEQFNSTYR-A2F.
Dependencies are inferred from the claim text.